共 50 条
- [21] Effects of Galcanezumab on Acute Medication Use, Time to Response, and Total Pain Burden in Patients with Episodic Cluster Headache: Post hoc Outcomes from a Phase 3, Randomized, Double-blind, Placebo-controlled StudyNEUROLOGY, 2020, 94 (15)Kudrow, DavidAndrews, J. ScottRettiganti, MallikarjunaOakes, TinaBardos, JenniferZhou, ChunmeiAurora, Sheena K.Kuruppu, DulanjiWenzel, RichardRiesenberg, RobertGaul, CharlyMartinez, James
- [22] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with GalcanezumabNEUROLOGY, 2017, 88Aurora, SheenaOakes, TinaZhang, QiAhl, JonnaMartinez, James
- [23] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with GalcanezumabNEUROLOGY, 2017, 88Aurora, SheenaOakes, TinaZhang, QiAhl, JonnaMartinez, James
- [24] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with GalcanezumabHEADACHE, 2017, 57 : 182 - 183Aurora, S. K.Oakes, T. M.Zhang, Q.Ahl, J.Martinez, J. M.
- [25] A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trialBLOOD ADVANCES, 2024, 8 (06) : 1494 - 1503Carcao, ManuelSchiavulli, MicheleKulkarni, RoshniRendo, PabloFoster, MeredithSantagostino, ElenaCasiano, SandraKoenigs, Christoph
- [26] Efficacy of Galcanezumab in Adults With Treatment Resistant Migraine and Concomitant Pain Disorders: Post-hoc Subpopulation Analyses From the Randomized, Double-Blind, Placebo-Controlled CONQUER StudyHEADACHE, 2020, 60 : 105 - 106Argoff, C.Dong, Y.Li, L. Q.Barad, M.Wright, P.
- [27] Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trialHEADACHE, 2025, 65 (01): : 101 - 112Gryglas-Dworak, AnnaSchim, JackEttrup, AndersBoserup, Line PickeringJosiassen, Mette KrogRanc, KristinaSperling, BjrnAshina, Messoud
- [28] Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysisHEADACHE, 2023, 63 (10): : 1351 - 1358Ashina, MessoudMitsikostas, Dimos D.Campos, Verena RamirezBarash, SteveNing, XiaopingDiener, Hans-Christoph
- [29] Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Clinical Drug Investigation, 2022, 42 : 277 - 277Stewart J. TepperJessica AilaniJanet H. FordRussell M. NicholsLily Q. LiPhebe KemmerAustin L. HandAntje Tockhorn-Heidenreich
- [30] Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trialCEPHALALGIA, 2021, 41 (10) : 1053 - 1064Schwedt, Todd J.Sahai-Srivastava, SomaMurinova, NataliaBirlea, MariusAhmed, ZubairDigre, KathleenLopez, KristinaMullally, WilliamBlaya, Maike TiedePippitt, KarlyCutrer, Fred MichaelDeLange, JustinSchecht, HowardRizzoli, PaulLane, JudyWald, JohnCortez, Melissa M.Martin, Vincent T.Spare, Nicole M.Hentz, Joseph G.Robert, TeriDodick, David W.